See the DrugPatentWatch profile for cosentyx

According to the prescribing information and clinical trials, the recommended starting dose of Cosentyx (secukinumab) for the treatment of moderate to severe plaque psoriasis is 300 mg. This dose is typically administered as a single injection at the recommended dose of 300 mg at Weeks 0, 1, and 2, followed by maintenance doses of 300 mg every 4 weeks.

However, the dose may vary depending on the patient's response to treatment and the severity of their psoriasis. In some cases, the dose may be increased to 150 mg every 4 weeks or decreased to 150 mg every 4 weeks if the patient does not respond to the initial dose.

It's essential to note that Cosentyx is a biologic medication that works by blocking the activity of interleukin-17A (IL-17A), a protein that plays a key role in the development of psoriasis. The medication is administered subcutaneously, and the dose is based on the patient's body weight.

Sources:

1. [1] Cosentyx Prescribing Information. (n.d.). Retrieved from <https://www.cosentyx.com/content/dam/cosentyx/us/en_us/documents/cosentyx-prescribing-information.pdf>
2. [2] National Psoriasis Foundation. (n.d.). Secukinumab (Cosentyx). Retrieved from <https://www.psoriasis.org/treatments/cosentyx>
3. [3] DrugPatentWatch.com. (n.d.). Secukinumab (Cosentyx). Retrieved from <https://www.drugpatentwatch.com/drug/Secukinumab-Cosentyx>

Cited Sources:

1. Cosentyx Prescribing Information. (n.d.). Retrieved from <https://www.cosentyx.com/content/dam/cosentyx/us/en_us/documents/cosentyx-prescribing-information.pdf>
2. National Psoriasis Foundation. (n.d.). Secukinumab (Cosentyx). Retrieved from <https://www.psoriasis.org/treatments/cosentyx>
3. DrugPatentWatch.com. (n.d.). Secukinumab (Cosentyx). Retrieved from <https://www.drugpatentwatch.com/drug/Secukinumab-Cosentyx>